Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Jane Chung
Expanding ADC Therapy: Jane Chung from Sutro Biopharma in an Engaging Conversation with PharmaShots
Shots:   Luvelta, an antibody-drug conjugate by Sutro Biopharma is designed to target FRα, expressed in ovarian cancer, developed and manufactured using the company’s proprietary cell-free technology, XpressCF   Today, at PharmaShots, we have Jane Chung, President and CEO at Sutro Biopharma, shedding on the ongoing REFRαME-O1 study evaluating luvelta   Sutro is now enrolling patients for the…
July 24, 2024
Viewpoints_Mina Makar
Inherited Retinal Disease Management: Brian Strem from Kiora Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots
Shots:   Recently, Kiora Pharmaceuticals received an upfront payment of $16M after inking the partnership agreement with Théa Open Innovation to develop and commercialize KIO-301 and is eligible to receive up to $285M   KIO-301 belongs to a new-generation drug called molecular switches that offer a path around damaged receptors rather than looking to repair gene mutation  …
July 15, 2024
Viewpoints_Xochitl Javier
Redefining Technology: Xochitl Javier from Thermo Fisher Scientific in Conversation with PharmaShots
Shots:  Raman Analyzers are widely used in the biopharma industry to analyze different substances. Based on the principles of Raman Spectroscopy, Raman Analyzers provide information about their chemical composition and structure when interacting with laser  Today, at PharmaShots, we have Xochitl Javier, Director, Product Management & Marketing, Thermo Fisher Scientific, shedding light on the TruScan…
July 8, 2024
Viewpoints_Andrew Menzies-Gow
AstraZeneca at ATS’24: Andrew Menzies-Gow from AstraZeneca in a Stimulating Conversation with PharmaShots
Shots:  AstraZeneca presented 59 abstracts, including 12 late-breaking posters at the American Thoracic Society, focussing on the unmet needs in COPD, EGPA, and other chronic respiratory diseases  Today, at PharmaShots, we have Andrew Menzies-Gow, sharing insights from the MANDARA study that evaluated Fasenra (benralizumab) for EGPA, a rare debilitating condition  Andrew stresses reducing the use…
July 3, 2024
Viewpoints_Jesse Mendelsohn
Drug Pricing & Rebate Management: Jesse Mendelsohn from Model N in Dialogue Exchange with PharmaShots
Shots:  Drug pricing reforms from the IRA continue to impact pharmaceutical companies. The rebates ensued from the IRA guidelines are heavily affecting the revenues of biopharma companies  Today, at PharmaShots we have Jesse Mendelsohn, Sr. Vice President at Model N shedding light on the company’s recently launched solution called Medicare Part D inflation rebate-per-unit  With…
July 1, 2024
VIEWPOINTS_Roy Maute_2024
Macrophage Checkpoint Therapy: Roy Maute from Pheast Therapeutics in a Riveting Conversation with PharmaShots
Shots:  Recently Pheast Therapeutics shared the preclinical data for PHST001, an anti-CD24 macrophage checkpoint inhibitor at the 20th Annual PEGS Boston Summit  Today, at PharmaShots, we had a dialogue exchange with Roy Maute, Cofounder and CEO of Pheast Therapeutics  Pheast Therapeutics currently plans to initiate a clinical trial in H1’25  Saurabh: Can you walk me…
June 26, 2024
VIEWPOINTS_Moitreyee Chatterjee-Kishore1_Kohei Shitara2_2024
Unlocking Approval: Moitreyee Chatterjee-Kishore from Astellas & Kohei Shitara in Conversation with PharmaShots
Shots:  East Asia and East Europe report significant incidences of Gastric Cancer. In 2022, Japan registered around 44,000 mortalities due to Gastric Cancer  VYLOY, an anti-claudin 18.2 (CLDN18.2) monoclonal antibody, received Japan’s approval in combination with chemotherapy for patients with HER2 -ve, CLDN18.2+ve, unresectable, advanced, or recurrent gastric cancer  Today, at PharmaShots we have Moitreyee…
June 24, 2024
Load more